With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

The European stock markets were mixed, though relatively flat in Monday trading as The Stoxx Europe 600 was off 0.04%, Germany's DAX dipped 0.01%, the FTSE 100 in London gained 0.04%, France's CAC 40 ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 ...

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...

Semaglutide is already available in Ireland through diabetes medication Ozempic. However, its producer Novo Nordisk uses the ...

Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...